Two prospective, randomized, double-blinded, phase III clinical trials were conducted at 53 sites in the United States to compare the IOP-lowering efficacy and safety of 0.2%<unk>  tartrate/0.5% timolol maleate fixed combination twice daily with 0.2%<unk>  tartrate three times daily or 0.5% timolol maleate twice daily in patients aged 18 or older who had ocular hypertension or glaucoma. When assessed over a 3-month period, pooled results from a total of 1159 patients showed significantly greater mean IOP decrease from baseline with the<unk>  combination (4.9-7.6 mmHg) than with<unk>  monotherapy (3.1-5.5 mmHg) or timolol monotherapy (4.3-6.2 mmHg) across all follow-up visits. Similar efficacy results were reported during 12-month follow-up: mean IOP decrease from baseline was 4.4-7.6 mmHg with<unk>  combination, compared to 2.7-5.5 mmHg with<unk>  and 3.9-6.2 mmHg with timolol. The incidence of treatment-related adverse events with the<unk>  combination was lower than that with<unk>  monotherapy but higher than that with timolol monotherapy. A 12-week prospective, randomized, double-blinded study in 371 glaucoma and ocular hypertension patients with inadequate IOP control on monotherapy compared the efficacy and safety of 0.2%<unk>  tartrate/0.5% timolol fixed combination twice daily with the concomitant use of 0.2%<unk>  tartrate twice daily and timolol 0.5% twice daily. The IOP-lowering effect of the fixed combination group was shown to be non-inferior to that of concomitant therapy. Incidence of adverse events was similar between groups.
Brimonidine/timolol
Dorzolamide/timolol
Brinzolamide/brimonidine
Atenolol/chlorthalidone
Travoprost/timolol
Latanoprost/timolol
Bimatoprost/timolol
Timolol